Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction
| Autor: | John-David Aubert, Dela Golshayan, Lucienne Juillerat-Jeanneret, Josip Mikulic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug media_common.quotation_subject Animals Drug Discovery Fibrosis/drug therapy Fibrosis/metabolism Fibrosis/pathology Humans Molecular Targeted Therapy Organ Specificity Inflammation Bioinformatics 03 medical and health sciences 0302 clinical medicine Fibrosis medicine Repurposing media_common Chemistry Drug discovery Organ dysfunction medicine.disease Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis Molecular Medicine medicine.symptom |
| Zdroj: | Journal of medicinal chemistry, vol. 61, no. 22, pp. 9811-9840 |
| Popis: | Fibrosis is an inadequate response to tissue stress with very few therapeutic options to prevent its progression to organ dysfunction. There is an urgent need to identify drugs with a therapeutic potential for fibrosis, either by designing and developing new compounds or by repurposing drugs already in clinical use which were developed for other indications. In this Perspective, we summarize some pathways and biological targets involved in fibrosis development and maintenance, focusing on common mechanisms between organs and diseases. We review the therapeutic agents under experimental development, clinical trials, or in clinical use for the treatment of fibrotic disorders, evaluating the reasons for the discrepancies observed between preclinical and clinical results. We also discuss the improvement that we envision in the development of therapeutic molecules able to achieve improved potential for treatment, including indirect modulators, targeting approaches, or drug combinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|